CTI Partners with St. Elizabeth Healthcare and Pulmotect to Open First Hospital Site for Phase-2 Clinical Trial Targeting COVID-19

“The COVID-19 pandemic demands an unprecedented response from the pharmaceutical and biotechnology communities, requiring innovation, collaboration, and prioritization of speed without the cost of safety,” said Tim Schroeder, Founder and CEO of CTI. "We are proud to have the opportunity to collaborate on such a response with the St. Elizabeth team and to work together to develop an effective treatment solution for those hardest hit by COVID-19."

CTI Partners with Pulmotect on Two Phase-2 Trials Targeting COVID-19

“We are thrilled to be working with Pulmotect on these programs,” remarked Timothy Schroeder, CEO of CTI. “The research into PUL-042 for the treatment of patients with COVID-19 is a prime example of how the scientific community can leverage existing science and approach it in an innovative way to develop treatments for novel diseases. We are privileged to be able to help develop these innovative strategies and bring treatments to those in need.”

CTI Partners with Humanigen for Planned Phase III Study for Lenzilumab for Coronavirus Treatment

“The COVID-19 pandemic demands an unprecedented response from the pharmaceutical and biotechnology communities, requiring innovation, collaboration, and prioritization of speed without the cost of safety,” remarked Tim Schroeder, founder and CEO of CTI. "We are proud to have the opportunity to collaborate on such a response with the Humanigen team and to work together to develop an effective treatment solution for those hardest hit by COVID-19.”

How CTI Can Help Fight the Impact of COVID-19

CTI is dedicated to helping our partners, team members, and communities work through the COVID-19 pandemic. Whether that means helping adjust programs impacted by the pandemic, developing new programs to help our sponsors create effective treatments for infected patients, or simply providing support to our communities and team members, we are here to help.

 

Infectious Diseases

Our experience in this area is specific to complex immunocompromised patient populations susceptible to opportunistic infections.

Learn More

COVID-19

CTI is dedicated to helping our partners, team members, and communities work through the COVID-19 pandemic. Whether that means helping adjust programs impacted by the pandemic, developing new programs to help our sponsors create effective treatments for infected patients, or simply providing support to our communities and team members, we are here to help.

Learn More

Late Phase & Expanded Access Programs

CTI has the global infrastructure, site relationships, and health outcomes expertise to execute Phase IV, Registry, and Expanded Access Programs effectively.

Learn More

Volunteer for a COVID-19 Study

Icon Careers Small Retina

Join our database of participants for future COVID-19 clinical research trials

Learn More

Join our team

Icon Careers Small Retina

CTI is always looking for talented individuals to work on life-changing therapies around the world

Learn More

Latest News

New Hires & Promotions

June 30, 2020